本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Oct. 14, 2025 /PRNewswire/ -- CoinLander, the blockchain investment system that turns real-world mortgages into stable crypto returns, has launched its innovative platform. Given the volatile nature of the crypto space, CoinLander offers some welcome stability, providing investors with a sustainable opportunity to earn returns starting from a 6% Annual Percentage Rate (APR) minimum through assets backed by tangible real estate. The platform's release marks a major convergence of traditional finance and Web3 tech, providing a new level of security and predictability. With CoinLander's stable yield, which targets an APR range above the industry average, the platform doesn't just offer new levels of defi stability—it offers new levels of performance to go with it. Founded in mid-2024, CoinLander taps into the vast investment potential of illiquid real-world mortgage debt and brings that potential to the masses via tokenization. The platform's founder, RΞN—a veteran of asset management and mortgage services with over 20 years of experience in TradFi (and a BAYC holder, to boot)—has efficiently merged the accessibility of Web3 with the security of tangible real estate. CoinLander Delivers High-Yield Crypto Returns Secured by Real-World Mortgages Secure real-world yields in 4 easy steps If the mechanics of mortgage debt investment leave you a little confused, you don't need to worry. CoinLander makes the whole investment process simple, transparent, and fully automated. Step 1: Choose from real estate-backed investment pools with clear details on potential returns, risk, and duration. Step 2: Invest using USDT stablecoins Step 3: Every month, receive interest from borrowers' mortgage payments directly to your wallet. Step 4: The principal is returned at the end of the loan term, ready to reinvest or withdraw. Gaining a predictable income securely When it comes to new token launches, trust can be in short supply in the crypto space. While many platforms offer speculative, fluctuating APYs that can disappear overnight, CoinLander's investments are all secured by liens on real-world properties. This gives token holders peace of mind that their returns are backed by a real, sustainable business model. With monthly yields providing predictable, passive income, the platform not only delivers reliable returns but has lowered the capital entry barriers to mortgage debt. In doing so, it's giving us all a chance to access real estate investment opportunities that have historically been limited to large institutional investors. To find out more about the platform and how you can invest securely in tokenized real estate, head over to Website | Twitter | Telegram | LinkedIn About Coinlander CoinLander is a pioneering Real World Asset (RWA) platform that bridges the gap between traditional finance and the digital asset economy. It tokenizes high-quality, real-life mortgage investments, allowing users to earn predictable monthly interest backed by tangible property assets. The platform transforms illiquid real estate debt into accessible, transparent digital investments, offering a stable alternative to the volatility of traditional crypto markets.
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- The Financial Times (FT) has released its 2025 Global EMBA Ranking, hitting a new milestone record of School of Management at Fudan University (the School) with its highest ranking ever. The WashU–Fudan Executive MBA program was ranked No. 1 globally, while the Fudan EMBA program retained its leading position among Chinese-taught programs for 4 consecutive years. With its four programs ranked among the world's top 25, the School has become the only business school worldwide with the most programs reaching an all-time high in ranking. Four Programs All-Time High in Ranking WashU-Fudan EMBA Program — Ranked No. 1 globallyNo. 1 worldwide in salary today and salary increase Fudan EMBA Program — Ranked No. 8 globallyNo. 1 among Chinese-taught programs for 4 consecutive yearsTop in multiple indices of salary today, salary increase, work experience (maintaining first position for 6 consecutive years), alumni network and research HKU-Fudan IMBA Programme — Ranked No. 19 globallyFirst globally among part-time MBA programsSalary increase ranked second globally (118% increase) among part-time MBA programsResearch ranked eighth globally BI-Fudan MBA Program — Ranked No. 21 globallyHighest in its 13-year FT ranking history Salary increase ranked second globally (123% increase)Alumni network ranked first globallyInternational faculty rated first among part-time MBA programs worldwide for 7 consecutive years Mission-driven: Leading in Management Education in China As the first joint EMBA program approved by China's Ministry of Education (MOE), the WashU-Fudan EMBA program was launched in 2002. With the adoption of a collaborative teaching model between two partners, the program has become a testimony to "developing China's best management talent into global business leaders." Ranked third worldwide in 2024, the program has quickly climbed to No. 1 globally this year, with its remarkable leading position in salary increase along the years. The Fudan EMBA program was among the first batch of Chinese-taught EMBA degree programs approved by China's MOE, aiming to develop senior executives in all walks of life. Holding its first place among Chinese-taught program for 4 consecutive years, the Fudan EMBA program prides itself this year for its leading outcomes in multiple indices including salary today, salary increase, work experience, alumni network and research. The School has demonstrated a steady growth in the global ranking since 2006—from a single program leading Chinese mainland along the years to multiple programs consistently recognized among the world's best. The School started to participate in the FT ranking with multiple programs in 2012, a confident step for its open evaluation of the School's overall competitiveness. As a result, it has become a global competitive school, with the most programs and participating alumni among all ranking institutions. This year's ranking results in particular, with all four programs in the top 25, underscore the School's strong commitment to talent development, faculty enhancement, disciplinary advancement, and global outreach. Alumni-empowered: Building a Global Alumni Network that Drives Career Success In the latest ranking, all four programs have been placed within the global top 20 for alumni network, a testament gained directly from alumni's feedback on career advancement, mentorship, and support for innovation and entrepreneurship, to the School's vibrant and high-achieving community. Today, the School has an active global community composed of over 60,000 alumni worldwide. Research Impact: Contributing China's Perspective to Global Management Scholarship The FT Global EMBA ranking places strong emphasis on research capability. Research strength of Fudan EMBA program has again been ranked first globally among Chinese–taught programs. In the recently released UTD Top 100 Business School Research Rankings, the School ranked 66th globally and maintained its position as the top school in Chinese mainland, marking its tenth consecutive year in the global top 100. A large number of research findings based on China's best practices were published on the leading international journals. The School has secured 21 research grants offered by the National Natural Science Foundation of China (NSFC), covering priority areas such as AI and emerging technologies, industrial transformation, and consumer innovation. The School continues to strengthen its Science and Technology Innovation Strategy through cross-disciplinary AI research initiatives and dedicated talent development pipelines, preparing the next generation of scholars and leaders. Embarking on a new journey of glory at the crossing of its 40th anniversary of re-establishment, School of Management, Fudan University will continue to uphold its spirit of 'Enlightening for Truth and Pioneering for Change,' relentlessly cultivating outstanding management talents who will not only lead China's economic development but also drive the engine of new global industrial revolution for the next century.
高雄2025年10月14日 /美通社/ -- 全球散熱品牌建準（SUNON）於 OCP Global Summit 2025 正式展出其全新開發的液冷散熱系統，專為伺服器與 AI 運算場景設計，透過模組化架構與高能源效率，為開放運算基礎設施提供更穩定、可靠的冷卻解決方案。 SUNON to Showcase Liquid Cooling Solutions at OCP Global Summit 2025 Collaborating with the Industry to Shape the Future of Open Compute 此次展出以「Build to Chill」為主題，呼應建準持續投入散熱技術研發的品牌精神，建準不僅致力於「建造」高效能冷卻系統，更期待打造能引領產業發展的「最佳」散熱方案。 本次正式亮相的三大核心液冷解決方案，涵蓋下列應用面向： 三大產品亮點介紹： 開放式水冷板（Cold Plate） 專為 Intel/AMD 架構伺服器 CPU 設計，實現高性能表現，並支援多種伺服器平台整合。 在產品策略上，建準展現「從標準品到高客製化」的服務能力，不僅提供即用型標準產品，也能依據客戶需求進行規格調整與功能延伸，確保滿足不同產業的專屬挑戰與高速運算需求。 CDU 冷卻液分配裝置（Coolant Distribution Unit） 推出水對水（Liquid to Liquid）CDU，此次發表的產品採用模組化設計, 以利彈性選擇方案, 並兼顧維護便利性。 封閉式液冷系統（Closed-Loop Liquid Cooling System） 封閉式液冷模組可透過不同的部件選擇, 達到多種應用場景的使用, 實現產品的高度化客製需求。 建準液冷解決方案優勢： 標準品研發力：建準亦具備完整的氣液冷產品線，協助客戶以高效率導入氣液冷散熱解決方案。 全方位解決方案：結合氣液冷的技術優勢，提供不同層級的完整散熱方案，兼顧效能、高品質與性價比，協助客戶應用於多元場景與未來擴展需求。 建準此次亦於現場設有產品實體展示與動態影片演示，邀請媒體、業界客戶與技術夥伴深入交流，了解最新液冷設計技術。會後亦提供客戶拜訪與產品簡報，協助客戶掌握完整產品架構與導入策略，建準將持續以創新冷卻技術推動開放架構發展，共創高效能與永續並存的運算未來。 【參觀資訊】 展會名稱：OCP Global Summit 2025 展出日期：2025年10月13日－16日 地點：San Jose Convention Center, California, USA SUNON 攤位編號：A53
TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, which is held in Berlin, Germany, from Oct 17 to 21, 2025. Abstract: 2242Title: Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapySession Date/Time: 10/19/2025, 12:00-12:45 CESTPoster Board Number: 1577P Currently, although there are many options for cancer immunotherapy, they still cannot meet the needs of clinical treatment, especially for advanced solid tumors defined as 'cold tumors'. Genetic alterations of certain receptor tyrosine kinases (TKs), including TAM (TYRO3, AXL, and c-MER), are critical in creating environment conducive to tumor development in several cancers such as HNSCC, CRC, HCC, and RCC. GNTbm-TKI is a novel multi-targeted TKI, showing induction of immune activation in the tumor microenvironment (TME), that indicates the potential application in cancer immunotherapy for unmet medical needs. The results of the study show that GNTbm-TKI strongly inhibited the activities of TYRO3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 at nanomolar level. GNTbm-TKI showed anti-proliferation activity in NCI-60 human cancer cell lines with low GI50 values. GNTbm-TKI showed a superior in vivo efficacy in WT mice compared to immune-deficient mice in CT-26 model, indicating anti-cancer immune activation induced by the treatment. Furthermore, treatment with GNTbm TKI + GNTbm-38 (an immune activator of class ⅠHDACi) combined with ICI significantly improved tumor response rate and boosted survival rate through synergistic effect by normalizing tumor vessels, increasing activated CD8+ T cell infiltration into tumors, inducing memory T cell persistence, and strongly inhibiting mobilization of immunosuppressive cells into tumors. On the other hand, GNTbm-TKI + GNTbm-38 combined with anti-PD-1/VEGF bispecific antibodies in a humanized B-PD-1/PD-L1/VEGFA mouse model also greatly improved anti-cancer with a strong synergistic effect. GNTbm-TKI is a potent immune-activating multi-tyrosine kinase inhibitor, and it is surprisingly found capable of significantly reshaping the tumor microenvironment when combined with GNTbm-38. When further combined with ICI or anti-PD-1/VEGF bispecific antibodies, it can greatly enhance anti-cancer efficacy, providing a scientific basis for future clinical trials. About GNTbm-TKIGNTbm-TKI is a new chemical entity independently developed by GNTbm. It is a drug candidate selected by an immuno-competent tumor-bearing animal testing platform, and has undergone many preclinical research studies to be demonstrated that it has very outstanding anti-cancer activity in tumor microenvironment. GNTbm-TKI is an oral drug with dual effects of strong immune activation and multi-tyrosine kinase, which is unique when compared to the mechanism of other TKI drugs. GNTbm-TKI can remodel the tumor microenvironment (TME) through a unique multiple regulatory mechanism based on its kinase targets which it selectively inhibits. GNTbm-TKI strongly inhibits tumor growth and development, suppresses tumor invasion and metastasis, inhibits tumor angiogenesis, and most importantly, possesses potent tumor immune regulatory activity. When GNTbm-TKI is combined with GNTbm-38, based on their respective unique mechanisms, they have a complementary and powerful tumor microenvironment remodeling function, capable of converting 'cold tumors' into 'hot tumors.' When further combined with ICI or anti-PD-1/VEGF bispecific antibodies, they exhibit exceptionally superior anti-tumor immuno-oncology activity, which can attract CTL to infiltrate into the TME, and activate CTLs and reduce CTL exhaustion. At the same time, it can also reduce the attraction of immunosuppressive cells (such as: TAM, Treg, and MDSCs) into the TME, so as to achieve the remodeling of the TME, which is more conducive to obtaining the therapeutic benefits of cancer immunotherapy. GNTbm-TKI monotherapy can be used in the treatment of advanced neuroendocrine tumor, and GNTbm-TKI can also be combined with GNTbm-38 or/and ICI/anti-PD-1/VEGF bispecific antibodies for treatment of a variety of solid tumors, mainly through a unique anti-cancer immune-regulating and multiple-tyrosine kinase inhibition mechanism to achieve anti-cancer treatment goals. About GNTbmGNTbm (stock code: 7427, Taiwan) is a company that has developed new drugs against advanced cancers, and has marketed a new drug approved for advanced Her-2-ER+ breast cancer in Taiwan. The GNTbm R&D team independently develops new drugs, and has multiple anti-cancer drug candidates with global development rights, with the goal of meeting the unmet clinical needs of patients with advanced cancers. GNTbm mainly focuses on the development of drugs with innovative mechanisms for the new generation of cancer immunotherapy, conducts clinical validation, and hopes to successfully provide novel immunotherapy with excellent efficacy and safety for varieties of cancer indications, to fulfil the unmet medical needs of patients around the world and improve the quality of life of patients.
台北2025年10月14日 /美通社/ -- 華上生醫簡稱GNTbm （股票代碼：7427）宣布其針對癌症免疫療法的全新免疫活化多重激酶抑制劑GNTbm-TKI的臨床前數據，將於2025年歐洲腫瘤醫學會（ESMO）年會上以海報形式發表，該會議將於2025年10月17日至10月21日在德國柏林舉行。 摘要編號: 2242題目: Preclinical development of GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor, while combined with GNTbm-38 showing potent induced tumor microenvironment remodeling activity in cancer immunotherapy海報展示時間: 10/19/2025, 12:00-12:45 CEST海報張貼號碼: 1577P 目前，儘管癌症免疫療法有許多選擇，但仍然還無法滿足臨床治療的需求，特別是針對被視為「冷腫瘤」的多種晚期實體腫瘤。研究顯示一些多重激酶的靶點，包括 TAM（TYRO3、AXL 和 c-MER）的基因變異，被發現在多種癌症（如頭頸部鱗狀細胞癌、結直腸癌、肝細胞癌和腎細胞癌）中，這些基因變異對於創造有利於腫瘤發展的環境中具有關鍵的作用。GNTbm-TKI 是一種新型的多重激酶抑制劑，能顯著誘導腫瘤微環境（TME）中的免疫激活作用，顯示其在未滿足臨床需求的腫瘤免疫療法中具有潛在應用價值。 華上生醫在本次ESMO的研究發表顯示，GNTbm-TKI 主要是強效抑制 TYRO3、AXL、c-MER、BTK、ROS1、NTRK2、MET 和 VEGFR2 的活性，在nM濃度下具有非常強的抑制效果。GNTbm-TKI 在 NCI-60 人類癌症細胞系中表現出強大的抗增殖活性，GI50 值低。GNTbm-TKI 在 CT-26 模型中，和免疫缺陷小鼠相比，在野生型小鼠（免疫健全）中顯示出優異的體內抗癌療效，顯示GNTbm-TKI的優越抗癌活性與免疫活化有關。此外，GNTbm-TKI 與 GNTbm-38（屬於第I 類 HDAC 抑制劑的免疫活化劑）並聯合 ICI 的組合治療，通過協同作用顯著提升腫瘤反應率和生存率，推測其可能的機制包括: 讓腫瘤血管正常化、增加活化 CD8+ T 及吸引細胞浸潤至腫瘤微環境中、誘導記憶 T 細胞的生成，以及強力抑制免疫抑制型細胞被腫瘤吸引至腫瘤微環境中。另一方面，研究也顯示GNTbm-TKI + GNTbm-38 聯合抗 PD-1/VEGF 雙特異性抗體，在人源化 B-PD-1/PD-L1/VEGFA 小鼠模型中，也極大地改善了抗癌效果，表現出強烈的協同增效作用。 GNTbm-TKI 是一種強效的免疫活化多激酶抑制劑，且發現其在與 GNTbm-38 聯合使用時能顯著重塑腫瘤微環境。當進一步與 ICI 或抗 PD-1/VEGF 雙特異性抗體聯合時，能大幅提升抗癌療效，為未來臨床試驗提供科學依據。 關於GNTbm-TKI GNTbm-TKI 是由 GNTbm 自主開發的一種新化學結構，作為新一代腫瘤免疫療法組合藥物中的重要組成藥物，具有非常強效的抗癌作用。它是藉由免疫健全的腫瘤動物測試平台選出的藥物候選物，並且已經進行了多項臨床前研究，以確認其作用在腫瘤微環境中具有非常出色的抗癌活性。GNTbm-TKI 是口服的藥物，具有強效免疫激活和多重激酶抑制的雙重作用，與其他的TKI 藥物機制相比具有免疫調控的獨特活性。GNTbm-TKI 可以通過基於其強效抑制激酶靶點的獨特多重調控機制大幅重塑腫瘤微環境（TME）。GNTbm-TKI主要是強效抑制腫瘤生長和發展，抑制腫瘤侵襲和轉移，抑制腫瘤血管生成，最重要的，具有強效的腫瘤免疫調節活性。當 GNTbm-TKI 與 GNTbm-38 聯合使用時，基於其各自獨特的作用機制，它們具有強大的互補性在調控腫瘤微環境的重塑，能夠將「冷腫瘤」轉化為「熱腫瘤」。當進一步與 ICI 或抗 PD-1/VEGF 雙特異性抗體聯合時，展現出極其卓越的抗腫瘤免疫腫瘤活性，能夠吸引 CTL 滲入腫瘤微環境（TME）中，並激活 CTL 及減少 CTL 衰竭。同時，也能降低免疫抑制型細胞（如 TAM、Treg 和 MDSC）被吸引浸潤在TME中，以達到重塑 TME 的效果，這些機制作用將更有利於獲得腫瘤免疫治療的效益。GNTbm-TKI 單藥治療可望用於治療晚期神經內分泌腫瘤，而GNTbm-TKI + GNTbm-38 或聯合 ICI/抗 PD-1/VEGF 雙特異性抗體將可用於多種晚期實體腫瘤的治療，主要通過其獨特的免疫調節活性和多重激酶抑制機制來實現抗癌治療目標。 關於華上生醫 華上生醫在台灣的股票代碼：7427，是一家從事抗癌新藥開發的公司，並在台灣市場上已經推出一種對抗HR+/Her-2-晚期乳癌的新成分新藥用於治療病患。華上生醫的研發團隊具備自主開發新藥的能力，擁有多個已申請全球專利的抗癌候選藥物的品系，目標是滿足患者未被滿足的臨床需求。華上生醫主要專注於開發創新機制的新藥物，針對新一代癌症免疫療法，進行臨床驗證，希望能成功開發出屬於創新癌症免疫療法可用於多種不同適應症治療藥物，可望提供更有效，且更安全的創新治療藥物，滿足全球晚期癌症患者的治療需求，並改善患者的生活品質，重拾病患與家人的美好時刻。
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- Strategic highlights – operational excellence and enhanced financial flexibility Strong commercial momentum with significant customer agreements including in India, Japan and the UK. Operational excellence and cost efficiency actions driving gross margins to strong sustainable levels. 5G Open RAN-ready portfolio breadth and technology leadership position reaffirmed by Gartner and Omdia. Financial highlights – further profitability growth Organic sales declined by -2%, with growth in three out of four market areas. Reported sales were SEK 56.2 (61.8) b., with an FX impact of SEK -4.2 b. Adjusted[1] gross income decreased to SEK 27.0 (28.6) b. as currency headwinds offset strong operational execution. Reported gross income was SEK 26.8 (28.2) b. Adjusted[1] gross margin was 48.1% (46.3%) driven by improvements in Networks and Cloud Software and Services. Reported gross margin was 47.6% (45.6%). Adjusted[1] EBITA was SEK 15.8 (7.8) b. with a 28.1% (12.6%) margin, including a SEK 7.6 b. capital gain benefit from the divestment of iconectiv. Reported EBITA was SEK 15.5 (6.2) b. with a 27.6% (10.0%) margin. Net income was SEK 11.3 (3.9) b. including a benefit from the capital gain. EPS diluted was SEK 3.33 (1.14). Free cash flow before M&A was SEK 6.6 (12.9) b. Net cash increased to SEK 51.9 b. Börje Ekholm, President and CEO, said: "In Q3, we established margins at a new long-term level following strong operational execution over the past few years. Cloud Software and Services sales grew 9%*, driven by strong growth in core networks. Our solid progress on technology initiatives continues. Gartner and Omdia reconfirmed our 5G solutions are industry leading. Our Open RAN-ready portfolio includes an AI native, future proof software architecture which is hardware agnostic. The portfolio integrates with third-party radios and supports Ericsson silicon and third-party CPU/GPUs. Looking ahead, we expect Enterprise organic sales to stabilize in Q4 and the RAN market to remain broadly stable. Solid recurring cash flow and the iconectiv sale contributed to a strong Q3 cash position, offering scope for increased shareholder distributions. The Board's recommendation on the scale and mechanism for the distribution will be included in the Q4 report for decision at the AGM." SEK b. Q3 2025 Q3 2024 YoY change Q2 2025 QoQchange Jan-Sep2025 Jan-Sep 2024 YoY change Net sales 56.239 61.794 -9 % 56.132 0 % 167.396 174.967 -4 % Organic sales growth * [2] - - -2 % - - - - 0 % Gross income 26.777 28.185 -5 % 26.649 0 % 79.963 76.658 4 % Gross margin [2] 47.6 % 45.6 % - 47.5 % - 47.8 % 43.8 % - EBIT (loss) 15.151 5.774 162 % 6.391 137 % 27.473 -3.6 - EBIT margin [2] 26.9 % 9.3 % - 11.4 % - 16.4 % -2.1 % - EBITA [2] 15.516 6.203 150 % 6.763 129 % 28.931 13.522 114 % EBITA margin [2] 27.6 % 10.0 % - 12.0 % - 17.3 % 7.7 % - Net income (loss) 11.300 3.881 191 % 4.626 144 % 20.143 -4.505 - EPS diluted, SEK 3.33 1.14 192 % 1.37 143 % 5.94 -1.43 - Free cash flow before M&A [2] 6.631 12.944 -49 % 2.581 157 % 11.916 24.210 -51 % Net cash, end of period [2] 51.858 25.534 103 % 36.040 44 % 51.858 25.534 103 % Adjusted financial measures [1][2] Adjusted gross income 27.048 28.609 -5 % 26.959 0 % 80.702 77.670 4 % Adjusted gross margin 48.1 % 46.3 % - 48.0 % - 48.2 % 44.4 % - Adjusted EBIT (loss) 15.454 7.327 111 % 7.047 119 % 28.713 -0.259 - Adjusted EBIT margin 27.5 % 11.9 % - 12.6 % - 17.2 % -0.1 % - Adjusted EBITA 15.819 7.756 104 % 7.419 113 % 30.171 16.908 78 % Adjusted EBITA margin 28.1 % 12.6 % - 13.2 % - 18.0 % 9.7 % - * Sales adjusted for the impact of acquisitions and divestments and effects of foreign currency fluctuations. [1] Adjusted metrics are adjusted to exclude restructuring charges. [2] Non-IFRS financial measures are reconciled at the end of this report to the most directly reconcilable line items in the financial statement. NOTES TO EDITORS You find the complete report with tables in the attached PDF or on www.ericsson.com/investors Video webcast for analysts, investors and journalists President and CEO Börje Ekholm and CFO Lars Sandström will comment on the report and take questions at a live video webcast at 9:00 AM CEST (8:00 AM BST London, 3:00 AM EDT New York). Join the webcast or please go to www.ericsson.com/investors To ask a question: Access dial-in information here The webcast will be available on-demand after the event and can be viewed at www.ericsson.com/investors. FOR FURTHER INFORMATION, PLEASE CONTACT Daniel Morris, Head of Investor Relations Phone: +44 7386657217 E-mail: investor.relations@ericsson.com Additional contacts Stella Medlicott, Senior Vice President, Marketing and Corporate Relations Phone: +46 730 95 65 39 E-mail: media.relations@ericsson.com InvestorsLena Häggblom, Director, Investor Relations Phone: +46 72 593 27 78 E-mail: lena.haggblom@ericsson.com Alan Ganson, Director, Investor Relations Phone: +46 70 267 27 30 E-mail: alan.ganson@ericsson.co Media Ralf Bagner, Head of Media Relations Phone: +46 76 128 47 89 E-mail: ralf.bagner@ericsson.com Media relations Phone: +46 10 719 69 92 E-mail: media.relations@ericsson.com This is information that Telefonaktiebolaget LM Ericsson is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CEST on October 14, 2025. This information was brought to you by Cision http://news.cision.com https://news.cision.com/ericsson/r/ericsson-reports-third-quarter-results-2025,c4249501 The following files are available for download: https://mb.cision.com/Main/15448/4249501/3720385.pdf Ericsson Q3 2025 ENG https://mb.cision.com/Public/15448/4249501/b4daaa7dd0442ddb.xlsx Q3-25 tables
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
